•
Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China Beijing International Fair for Trade in Services (CIFTIS) to establish a smart manufacturing and biomedical digital empowerment center. The initiative, leveraging AWS’s cloud, AI, and IoT technologies, aims to accelerate industrial upgrading in the Guangdong…
•
Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher Life Sciences China to develop smart automation solutions. The collaboration targets lab automation and applications in drug screening, biopharmaceuticals, and cell gene therapy, combining both companies’ technical strengths. Partnership DetailsThe alliance will integrate MegaRobo’s AI-powered…
•
Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision medicine, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by Legend Capital. The funds will allow the company to double down on mass spectrometry multi-omics…
•
Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of a USD95 million Series D financing round following Series D2 funding. The round was led by Saudi Aramco’s Prosperity7 Ventures. The proceeds will be used to advance its in-house developed product pipeline and accelerate pivotal…
•
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with BrainCo, a firm operating in China and the U.S., to launch the latter’s ADHD product in China. Financial details of the deal were not disclosed. Product DetailsThe ADHD product features a smart, non-invasive brain-computer interface…
•
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging its DNA Encoded Library (DEL) technology to screen compounds for targets identified by LoQus23. The collaboration aims to develop small-molecule drugs targeting DNA mismatch repair (MMR) to slow neurodegeneration in diseases like Huntington’s and myotonic…
•
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a three-year partnership with Huawei Technologies Co., Ltd to explore the application of artificial intelligence (AI) in drug development. The collaboration will focus on macro and small molecule drug design, related diseases, and database development. Partnership…
•
Guangzhou-based AI biotech Fermion has raised over RMB100 million ($14.8 million) in a Series B financing round led by iFLYTEK Venture Capital, Zhengxuan Capital, Panda Capital, and Challenjers Venture Capital. The funds will advance its core drug pipelines, including a Phase I clinical study for FZ002, a chronic pain candidate,…